Company intelligence / Profile preview

Vincentage Pharma Co., Ltd.

Kunshan*†, Jiangsu Sheng*, Chinavincentage.com ↗

Ownership: Private
Development stage: Other

Overview

The company’s lead candidate, VCT220/CX11, an oral small molecule GLP‑1 receptor agonist, has shown up to −5.8% weight loss in obese patients and up to −1% HbA1c reduction in type 2 diabetes patients with a favorable safety profile and no drug-related serious adverse events reported. A pivotal Phase 3 trial began recently in China; ex-China rights have been licensed to Corxel Pharmaceuticals, which will begin global Phase 2 trials in obesity/overweight.[2][6][7]

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Small molecules[1][2][5]
Industry: Biotech

Partnerships

Corxel Pharmaceuticals – acquired worldwide rights excluding Greater China for VCT220/CX11 as of December 2024[5]

Beyond the preview

Go deeper on Vincentage Pharma Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vincentage Pharma Co., Ltd..